Survival rates and safety associated with chemoradiotherapy followed by surgery and chemoradiotherapy alone for patients with T4 esophageal cancer: a systematic review and meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer  statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–130.
   PubMed Web of Science ®Google Scholar
• Holscher AH, Bollschweiler E, Bumm R, et al. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery. 1995;118(5):845–855.
   PubMed Web of Science ®Google Scholar
• Tabira Y, Yasunaga M, Nakano KY, et al. All pathological T4 esophageal carcinomas should be categorized as stage IV. Hepatogastroenterology. 2002;49(45):694–698.
   PubMedGoogle Scholar
• Fockens P, Kisman K, Merkus MP, et al. The prognosis of esophageal carcinoma staged irresectable (T4) by endosonography. J Am Coll Surg. 1998;186(1):17–23.
   PubMed Web of Science ®Google Scholar
• de Manzoni G, Pedrazzani C, Pasini F, et al. Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol. 2007; 95(3):261–266.
   PubMed Web of Science ®Google Scholar
• Chen HY, Ma XM, Ye M, et al. Esophageal perforation during or after conformal radiotherapy for esophageal carcinoma. J Radiat Res. 2014;55(5):940–947.
   PubMed Web of Science ®Google Scholar
• Shinoda M, Ando N, Kato K, Japan Clinical Oncology Group, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106(4):407–412.
   PubMed Web of Science ®Google Scholar
• Fujita H, Sueyoshi S, Tanaka T, et al. Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 2005;29(1):25–30. discussion 30–1.
   PubMed Web of Science ®Google Scholar
• Satake H, Tahara M, Mochizuki S, et al. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol. 2016;78(1):91–99.
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17(9):2915–2921.
   PubMed Web of Science ®Google Scholar
• Shapiro J, van Lanschot JJB, Hulshof M, CROSS study group, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–1098.
   PubMed Web of Science ®Google Scholar
• Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). radiation therapy oncology group. JAMA. 1999; May 5281(17):1623–1627.
   Google Scholar
• Vellayappan BA, Soon YY, Ku GY, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev. 2017;8:CD010511.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang L, He B, et al. Development and validation of a risk prediction model for radiotherapy-related esophageal fistula in esophageal cancer. Radiat Oncol. 2019;14(1):181.
   PubMed Web of Science ®Google Scholar
• Zhu C, Wang S, You Y, et al. Risk factors for esophageal fistula in esophageal cancer patients treated with radiotherapy: a systematic review and Meta-Analysis. Oncol Res Treat. 2020;43(1-2):34–41.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Z, Zhang W, et al. Risk factors for esophageal fistula in patients with locally advanced esophageal carcinoma receiving chemoradiotherapy. Onco Targets Ther. 2018;11:2311–2317.
   PubMed Web of Science ®Google Scholar
• Kim H, Oh D, Ahn YC, et al. Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion. Radiat Oncol. 2018;13(1):245.
   PubMed Web of Science ®Google Scholar
• Makino T, Yamasaki M, Tanaka K, et al. Treatment and clinical outcome of clinical T4 esophageal cancer: a systematic review. Ann Gastroenterol Surg. 2019;3(2):169–180.
   PubMed Web of Science ®Google Scholar
• Richardson WS, Wilson MC, Nishikawa J, et al. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995; 123(3):A12–3.
   PubMedGoogle Scholar
• Ebell M. Information at the point of care: answering clinical questions. J Am Board Fam Pract. 1999; 12(3):225–235.
   PubMedGoogle Scholar
• Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annu Symp Proc. 2006;2006:359–363.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• J H. Levels of evidence. Oxford Centre for Evidence-Based Medicine. March 2009.
   Google Scholar
• Wells G, Shea B. D OC. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2013. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Studio R. Integrated development environment for R. 2015. Accessed 25 February, 2020. https://rstudio.com/products/rstudio/.
   Google Scholar
• Viechtbauer W. Conducting Meta-analyses in R with the metafor package. J Statistical Software. 2010;36(3):1–48.
   Web of Science ®Google Scholar
• Balduzzi S, Rucker G, Schwarzer G. How to perform a Meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160.
   PubMed Web of Science ®Google Scholar
• Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Statist. 1950;21(4):607–611.
   Google Scholar
• Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods. 2019;10(1):83–98.
   PubMed Web of Science ®Google Scholar
• Ades AE, Lu G, Higgins JP. The interpretation of random-effects Meta-analysis in decision models. Med Decis Making. 2005; 25(6):646–654.
   PubMed Web of Science ®Google Scholar
• Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol. 1991;44(2):127–139.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Wg C. The combination of estimates from different experiments. Biometrics. 1954;10(1):101–129.
   Web of Science ®Google Scholar
• Rucker G, Schwarzer G, Carpenter JR, et al. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8:79.
   PubMed Web of Science ®Google Scholar
• Serghiou S, Goodman SN. Random-effects meta-analysis: summarizing evidence with caveats. JAMA. 2019;321(3):301–302.
   PubMed Web of Science ®Google Scholar
• IntHout J, Ioannidis JP, Rovers MM, et al. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open. 2016;6(7):e010247.
   PubMed Web of Science ®Google Scholar
• Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan esophageal oncology group (JEOG)/Japan clinical oncology group trial (JCOG9516). Jpn J Clin Oncol. 2004;34(10):615–619.
   PubMed Web of Science ®Google Scholar
• Kaneko K, Ito H, Konishi K, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003;88(1):18–24.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Sohda M, Tanaka N, et al. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2015;75(3):449–455.
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Suzuki M, Nakamatsu K, et al. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys. 2002;53(1):134–139.
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Yoshida S, Boku N, et al. Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol. 1995;25(6):261–266.
   PubMed Web of Science ®Google Scholar
• Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328–1334.
   PubMed Web of Science ®Google Scholar
• Shimoji H, Karimata H, Nagahama M, et al. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg. 2013;37(9):2180–2188.
   PubMed Web of Science ®Google Scholar
• Okamura A, Hayami M, Kozuki R, et al. Salvage esophagectomy for initially unresectable locally advanced T4 esophageal squamous cell carcinoma. Esophagus. 2020;17(1):59–66.
   PubMed Web of Science ®Google Scholar
• Miyata H, Yamasaki M, Kurokawa Y, et al. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol. 2012;106(4):441–447.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14(3-4):197–201.
   PubMed Web of Science ®Google Scholar
• Akutsu Y, Matsubara H. Chemoradiotherapy and surgery for T4 esophageal cancer in Japan. Surg Today. 2015;45(11):1360–1365.
   PubMed Web of Science ®Google Scholar
• Booka E, Haneda R, Ishii K, et al. Appropriate candidates for salvage esophagectomy of initially unresectable locally advanced T4 esophageal squamous cell carcinoma. Ann Surg Oncol. 2020;27(9):3163–3170.
   PubMed Web of Science ®Google Scholar
• Defize IL, van der Horst S, Bulbul M, et al. Salvage Robot-Assisted minimally invasive esophagectomy (RAMIE) for T4b esophageal cancer after definitive chemoradiotherapy. Ann Surg Oncol. 2021;28(5):2730–2738.
   PubMed Web of Science ®Google Scholar
• Miyoshi N, Yano M, Takachi K, et al. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. J Surg Oncol. 2009;99(5):302–306.
   PubMed Web of Science ®Google Scholar
• Morimoto H, Fujiwara Y, Lee S, et al. Treatment results of neoadjuvant chemoradiotherapy followed by radical esophagectomy in patients with initially inoperable thoracic esophageal cancer. Jpn J Radiol. 2018;36(1):23–29.
   PubMed Web of Science ®Google Scholar
• Noguchi T, Moriyama H, Wada S, et al. Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma. Dis Esophagus. 2003;16(2):94–98.
   PubMed Web of Science ®Google Scholar
• Ohira M, Kubo N, Masuda G, et al. Glasgow prognostic score as a prognostic clinical marker in T4 esophageal squamous cell carcinoma. Anticancer Res. 2015;35(9):4897–4901.
   PubMed Web of Science ®Google Scholar
• Ohkura Y, Ueno M, Iizuka T, et al. Prognostic factors and appropriate lymph node dissection in salvage esophagectomy for locally advanced T4 esophageal cancer. Ann Surg Oncol. 2019;26(1):209–216.
   PubMed Web of Science ®Google Scholar
• Pimiento JM, Weber J, Hoffe SE, et al. Outcomes associated with surgery for T4 esophageal cancer. Ann Surg Oncol. 2013;20(8):2706–2712.
   PubMed Web of Science ®Google Scholar
• Seto Y, Chin K, Gomi K, et al. Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci. 2007;98(7):937–942.
   PubMed Web of Science ®Google Scholar
• Sugawara K, Yagi K, Okumura Y, et al. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma. Int J Clin Oncol. 2020;25(4):552–560.
   PubMed Web of Science ®Google Scholar
• Van Raemdonck D, Van Cutsem E, Menten J, et al. Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration. Eur J Cardiothorac Surg. 1997; 1(5):828–837.
   Web of Science ®Google Scholar
• Yamaguchi S, Morita M, Yamamoto M, et al. Long-Term outcome of definitive chemoradiotherapy and induction chemoradiotherapy followed by surgery for T4 esophageal cancer with tracheobronchial invasion. Ann Surg Oncol. 2018;25(11):3280–3287.
   PubMed Web of Science ®Google Scholar
• Yano M, Tsujinaka T, Shiozaki H, et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol. 1999;70(1):25–32.
   PubMed Web of Science ®Google Scholar
• Crosby TD, Brewster AE, Borley A, et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90(1):70–75.
   PubMed Web of Science ®Google Scholar
• Font A, Arellano A, Fernandez-Llamazares J, et al. Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. Clin Transl Oncol. 2007;9(3):177–182.
   PubMed Web of Science ®Google Scholar
• Jingu K, Umezawa R, Matsushita H, et al. Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan. Int J Clin Oncol. 2016;21(2):276–282.
   PubMed Web of Science ®Google Scholar
• Li M, Zhao F, Zhang X, et al. Involved-field irradiation in definitive chemoradiotherapy for T4 squamous cell carcinoma of the esophagus. Curr Oncol. 2016;23(2):e131–e137.
   PubMed Web of Science ®Google Scholar
• Makino T, Doki Y. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg. 2011;17(3):221–228.
   PubMed Web of Science ®Google Scholar
• Soror T, Kho G, Zhao KL, et al. Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Dis. 2018;10(7):4069–4076.
   PubMed Web of Science ®Google Scholar
• Perez RO, Habr-Gama A, Sao Juliao GP, et al. Optimal timing for assessment of tumor response to neoadjuvant chemoradiation in patients with rectal cancer: do all patients benefit from waiting longer than 6 weeks? Int J Radiat Oncol Biol Phys. 2012;84(5):1159–1165.
   PubMed Web of Science ®Google Scholar
• Garcia-Aguilar J, Smith DD, Avila K, Timing of Rectal Cancer Response to Chemoradiation Consortium, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254(1):97–102.
   PubMed Web of Science ®Google Scholar
• Shang QX, Yang YS, Gu YM, et al. Timing of surgery after neoadjuvant chemoradiotherapy affects oncologic outcomes in patients with esophageal cancer. WJGO. 2020;12(6):687–698.
   Web of Science ®Google Scholar
• Zhang HZ, Jin GF, Shen HB. Epidemiologic differences in esophageal cancer between asian and Western populations. Chin J Cancer. 2012;31(6):281–286.
   PubMed Web of Science ®Google Scholar
• Hulshof M, Geijsen ED, Rozema T, et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study). J Clin Oncol. 2021;39(25):2816–2824.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–1203.
   PubMed Web of Science ®Google Scholar
• Lin SH, Hobbs BP, Verma V, et al. Randomized phase IIB trial of proton beam therapy versus Intensity-Modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol. 2020; 38(14):1569–1579.
   PubMed Web of Science ®Google Scholar